๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Epidermis

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) NCT06415487Phase 19 sites๐Ÿ“ San Diego๐Ÿ“ Denver๐Ÿ“ Nashville Acepodia Biotech, Inc. ยท Tests: Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab A Phase 2 Study of Mutant-selective PI3Kฮฑ Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) NCT06789913Phase 240 sites๐Ÿ“ Phoenix๐Ÿ“ Little Rock๐Ÿ“ Los Angeles Relay Therapeutics, Inc. ยท Tests: RLY-2608, Placebo A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Boston Taiho Oncology, Inc. ยท Tests: TAS6417, CYP Cocktail, Transporter Cocktail A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged โ‰ฅ2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome NCT07285005Phase 35 sites๐Ÿ“ Charleston๐Ÿ“ Daegu๐Ÿ“ Seoul Kaken Pharmaceutical ยท Tests: KP-001, Placebo Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents NCT06745557Phase 319 sites๐Ÿ“ Liรจge๐Ÿ“ Lyon๐Ÿ“ Marseille CUTISS AG ยท Tests: denovoSkin(TM), STSG Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study NCT06121232NA1 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Abbottยฎ DRG / Abbottยฎ/Medtronicยฎ SCS, Control Group Epidermal Skin Grafts to Improve Healing In Radiation Wounds NCT04560803NA1 site๐Ÿ“ Boston Massachusetts General Hospital ยท Tests: CelluTomeTM Epidermal Harvesting System HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 NCT06369831Phase 27 sites๐Ÿ“ Innsbruck๐Ÿ“ Brussels๐Ÿ“ Brussels Abscint NV/SA ยท Tests: 68Ga-NOTA-ABSCINT-HER2 PET/CT To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site๐Ÿ“ Suzhou Allist Pharmaceuticals, Inc. ยท Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII NCT07326566Phase 235 sites๐Ÿ“ Birmingham๐Ÿ“ Springdale๐Ÿ“ La Jolla Black Diamond Therapeutics, Inc. ยท Tests: silevertinib in combination with temozolomide, temozolomide (TMZ) A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer NCT07100106Phase 1, Phase 277 sites๐Ÿ“ Huntsville๐Ÿ“ Tucson๐Ÿ“ Duarte Genentech, Inc. ยท Tests: GDC-4198, Giredestrant, Abemaciclib Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction NCT07183423NA1 site๐Ÿ“ Makati City Makati Medical Center ยท Tests: Novel barrier repair topical product, Petrolatum RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan NCT05573893n/a109 sites๐Ÿ“ Amberg๐Ÿ“ Ansbach๐Ÿ“ Apolda AstraZeneca A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer NCT07049055Phase 1, Phase 24 sites๐Ÿ“ El Segundo๐Ÿ“ Summit๐Ÿ“ New York Engeneic Pty Limited ยท Tests: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel. ABY-029 Glioma Trial NCT07063693Phase 11 site๐Ÿ“ Lebanon Dartmouth-Hitchcock Medical Center ยท Tests: ABY-029 Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab NCT05760612Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Trastuzumab and neratinib, Trastuzumab and Pertuzumab Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites๐Ÿ“ Changchun๐Ÿ“ Chengdu๐Ÿ“ Dongguan Sun Yat-sen University ยท Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635Phase 217 sites๐Ÿ“ Santa Monica๐Ÿ“ Skokie๐Ÿ“ Billings Merck Sharp & Dohme LLC ยท Tests: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer NCT07658183Phase 21 site๐Ÿ“ Shanghai Shanghai Best-Link Bioscience, LLC ยท Tests: BL0175 Injection, BL0175 Injection Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer. NCT07227233Phase 21 site๐Ÿ“ La Jolla University of California, San Diego ยท Tests: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant., Treatment of physiciaโ€ฆ The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer NCT06452706Phase 216 sites๐Ÿ“ Bozhou๐Ÿ“ Chuzhou๐Ÿ“ Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharโ€ฆ ยท Tests: TQB2102 for injection Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors NCT05985655Phase 1, Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ New York Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: GTAEXS617, SoC A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer NCT06369285Phase 253 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Beverly Hills Puma Biotechnology, Inc. ยท Tests: Alisertib, Endocrine therapy Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites๐Ÿ“ St Leonards๐Ÿ“ Nedlands๐Ÿ“ Perth RayzeBio, Inc. ยท Tests: RYZ211/212
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy